Literature DB >> 30167789

Patient experience of head and neck lymphedema therapy: a qualitative study.

Jie Deng1, Robert J Sinard2, Barbara Murphy2.   

Abstract

PURPOSE: Lymphedema is a common late effect from head and neck cancer and/or its treatment. Guidelines recommend that patients with lymphedema should be referred for therapy in a timely manner to maximize control of lymphedema-related symptoms. However, there is paucity of information regarding treatment outcomes in the head and neck cancer population. To address this gap, we conducted a qualitative study to gain understanding of head and neck cancer patients' experience pertaining to lymphedema therapy, barriers to treatment, perceptions concerning physical and psychological benefits, opinions about therapists, and suggestions to enhance outcomes.
METHODS: Twenty head and neck cancer patients who underwent lymphedema therapy completed semi-structured face-to-face interviews. Interviews were audio-recorded, and verbatim transcriptions were completed. Thematic analysis was employed to analyze the interview data.
RESULTS: A majority of the participants (n = 15, 75%) completed a full course of lymphedema treatment. Most participants expressed physical (n = 18, 90%) and psychological (n = 14, 70%) benefits about the lymphedema therapy, e.g., decreased swelling, increased swallowing function, and multi-faceted healing. More than one third of the participants described barriers hampering their lymphedema therapy, e.g., insurance coverage, return to work, and availability of lymphedema therapy. Many participants proposed suggestions for improvement of lymphedema therapy, e.g., personalized education, longer treatment time, and caregiver education.
CONCLUSIONS: The study has underscored the potential benefit of lymphedema therapy in the head and neck cancer population. Substantial barriers to therapy were reported and need to be addressed. Opportunities to improve lymphedema therapy outcomes were suggested. Personalized strategies should be considered for ensuring optimal patient outcomes.

Entities:  

Keywords:  Experience; Head and neck cancer; Lymphedema; Lymphedema therapy; Qualitative

Mesh:

Year:  2018        PMID: 30167789     DOI: 10.1007/s00520-018-4428-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

1.  Preliminary development of a lymphedema symptom assessment scale for patients with head and neck cancer.

Authors:  Jie Deng; Sheila H Ridner; Barbara A Murphy; Mary S Dietrich
Journal:  Support Care Cancer       Date:  2011-11-10       Impact factor: 3.603

Review 2.  Manual lymphatic drainage for lymphedema following breast cancer treatment.

Authors:  Jeanette Ezzo; Eric Manheimer; Margaret L McNeely; Doris M Howell; Robert Weiss; Karin I Johansson; Ting Bao; Linda Bily; Catherine M Tuppo; Anne F Williams; Didem Karadibak
Journal:  Cochrane Database Syst Rev       Date:  2015-05-21

3.  Investigating the Short-Term Effects of Manual Lymphatic Drainage and Compression Garment Therapies on Lymphatic Function Using Near-Infrared Imaging.

Authors:  Catalina Lopera; Peter R Worsley; Dan L Bader; Deborah Fenlon
Journal:  Lymphat Res Biol       Date:  2017-07-27       Impact factor: 2.589

4.  A Review of Treatment for Breast Cancer-Related Lymphedema: Paradigms for Clinical Practice.

Authors:  Timothy D Smile; Rahul Tendulkar; Graham Schwarz; Douglas Arthur; Stephen Grobmyer; Stephanie Valente; Frank Vicini; Chirag Shah
Journal:  Am J Clin Oncol       Date:  2018-02       Impact factor: 2.339

Review 5.  Lymphedema management in head and neck cancer.

Authors:  Brad G Smith; Jan S Lewin
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2010-06       Impact factor: 2.064

Review 6.  Assessment and measurement of head and neck lymphedema: state-of-the-science and future directions.

Authors:  Jie Deng; Sheila H Ridner; Joseph M Aulino; Barbara A Murphy
Journal:  Oral Oncol       Date:  2015-02-20       Impact factor: 5.337

7.  Treatment and outcomes of head and neck oedema referrals to a hospital-based lymphoedema service.

Authors:  Eunice Jeffs; Martine Huit
Journal:  Br J Community Nurs       Date:  2015-04

8.  Perceived Symptom Experience in Head and Neck Cancer Patients with Lymphedema.

Authors:  Jie Deng; Sheila Ridner; Russell Rothman; Barbara Murphy; Kerry Sherman; Lee Moore; Kourtney Hall; Betsy Weiner
Journal:  J Palliat Med       Date:  2016-09-12       Impact factor: 2.947

9.  Internal Lymphedema Correlates with Subjective and Objective Measures of Dysphagia in Head and Neck Cancer Patients.

Authors:  Leanne K Jackson; Sheila H Ridner; Jie Deng; Carmin Bartow; Kyle Mannion; Ken Niermann; Jill Gilbert; Mary S Dietrich; Anthony J Cmelak; Barbara A Murphy
Journal:  J Palliat Med       Date:  2016-05-26       Impact factor: 2.947

Review 10.  American Cancer Society Head and Neck Cancer Survivorship Care Guideline.

Authors:  Ezra E W Cohen; Samuel J LaMonte; Nicole L Erb; Kerry L Beckman; Nader Sadeghi; Katherine A Hutcheson; Michael D Stubblefield; Dennis M Abbott; Penelope S Fisher; Kevin D Stein; Gary H Lyman; Mandi L Pratt-Chapman
Journal:  CA Cancer J Clin       Date:  2016-03-22       Impact factor: 508.702

View more
  3 in total

1.  A Pre-clinical Animal Model of Secondary Head and Neck Lymphedema.

Authors:  Giulia Daneshgaran; Andrea Y Lo; Connie B Paik; Michael N Cooper; Cynthia Sung; Wan Jiao; Sun Y Park; Pauline Ni; Roy P Yu; Ivetta Vorobyova; Tea Jashashvili; Young-Kwon Hong; Gene H Kim; Peter S Conti; Yang Chai; Alex K Wong
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

2.  Self-care for head and neck cancer survivors with lymphedema and fibrosis: study protocol for a randomized controlled trial.

Authors:  Jie Deng; Mary S Dietrich; Barbara Murphy
Journal:  Trials       Date:  2019-12-27       Impact factor: 2.279

3.  Advanced pneumatic compression for treatment of lymphedema of the head and neck: a randomized wait-list controlled trial.

Authors:  Sheila H Ridner; Mary S Dietrich; Jie Deng; Sandra L Ettema; Barbara Murphy
Journal:  Support Care Cancer       Date:  2020-06-02       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.